Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

June X Zou

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Cancer Research|September 25, 2010
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2Ekaterina V Kalashnikova, Alexey S Revenko, Abigael T Gemo, et al.
Cell Death and Differentiation|September 10, 2016
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapyJunjian Wang, Haibin Wang, Ling-Yu Wang, et al.
Cancer Letters|May 11, 2016
Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymesJunjian Wang, Zhijian Duan, Zoann Nugent, et al.
Plos One|April 6, 2012
MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growthNagalakshmi Nadiminty, Ramakumar Tummala, Wei Lou, et al.
Cell Reports. Medicine|May 1, 2024
Tumor mitochondrial oxidative phosphorylation stimulated by the nuclear receptor RORγ represents an effective therapeutic opportunity in osteosarcomaJianwei Zheng, Qianqian Wang, Jianghe Chen, et al.
Oncotarget|August 27, 2015
ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinomaCamilla Krakstad, Ingvild L Tangen, Erling A Hoivik, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2024
Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogrammingYatian Yang, Xiong Zhang, Demin Cai, et al.
Molecular Cancer Therapeutics|July 5, 2015
CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor RadioresistanceRui Liu, Ming Fan, Demet Candas, et al.
Nature Medicine|March 29, 2016
ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancerJunjian Wang, June X Zou, Xiaoqian Xue, et al.
Nature Communications|October 13, 2019
RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtypeDemin Cai, Junjian Wang, Bei Gao, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Research|September 25, 2010
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2Ekaterina V Kalashnikova, Alexey S Revenko, Abigael T Gemo, et al.
Cell Death and Differentiation|September 10, 2016
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapyJunjian Wang, Haibin Wang, Ling-Yu Wang, et al.
Cancer Letters|May 11, 2016
Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymesJunjian Wang, Zhijian Duan, Zoann Nugent, et al.
Plos One|April 6, 2012
MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growthNagalakshmi Nadiminty, Ramakumar Tummala, Wei Lou, et al.
Cell Reports. Medicine|May 1, 2024
Tumor mitochondrial oxidative phosphorylation stimulated by the nuclear receptor RORγ represents an effective therapeutic opportunity in osteosarcomaJianwei Zheng, Qianqian Wang, Jianghe Chen, et al.
Oncotarget|August 27, 2015
ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinomaCamilla Krakstad, Ingvild L Tangen, Erling A Hoivik, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2024
Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogrammingYatian Yang, Xiong Zhang, Demin Cai, et al.
Molecular Cancer Therapeutics|July 5, 2015
CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor RadioresistanceRui Liu, Ming Fan, Demet Candas, et al.
Nature Medicine|March 29, 2016
ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancerJunjian Wang, June X Zou, Xiaoqian Xue, et al.
Nature Communications|October 13, 2019
RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtypeDemin Cai, Junjian Wang, Bei Gao, et al.
Pageof 4